// App-Quantinova.ai

3023 : Exposure versus efficacy/safety of acalabrutinib and its pharmacologically active metabolite, ACP-5862, for the treatment of chronic lymphocytic leukemia

Researchers

Presenter

  • Helena Edlund

Principal Investigators

  • Karthick Vishwanathan

  • Ming Yin

  • Rakesh Raman

  • Min de Kock

  • Zhongqing He

  • Huan Liu

  • Marshall Baek

  • Nidal Al-Huniti

  • Joseph Ware

  • Shringi Sharma

Medical Centers

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca, Boston, MA

  • Acerta Pharma, South San Francisco, CA

Locations

  • Sweden

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • B cell lymphomas

  • Thrombocytopenia

  • Hypertension

  • Neutropenia

  • Anemia

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • ACP-196

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved